Lexicon To Present Study Results Relating To Sotagliflozin And LX9211 At The 59th Annual Meeting Of The European Association For The Study Of Diabetes
Portfolio Pulse from Benzinga Newsdesk
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) announced several upcoming data presentations related to heart failure, type 1 diabetes, and diabetic peripheral neuropathic pain at the 59th Annual Meeting of EASD. The presentations will include results from studies on INPEFA® (sotagliflozin), recently approved by FDA for heart failure treatment, and LX9211, an investigational, non-opioid treatment for diabetic peripheral neuropathic pain. LX9211 has received Fast Track designation from the FDA and is expected to advance into late-stage development before the end of 2023.
September 26, 2023 | 1:22 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Lexicon Pharmaceuticals is set to present data on INPEFA and LX9211, which could potentially impact the company's stock. LX9211 is expected to advance into late-stage development by the end of 2023.
The announcement of Lexicon's upcoming presentations at a major conference, along with the advancement of LX9211 into late-stage development, could potentially boost investor confidence and positively impact the company's stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100